1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99325
    Toralizumab

    托拉珠单抗

    Inhibitor 99.57%
    Toralizumab (IDEC-131) 是一种靶向 CD40L (CD154) 的人源化单克隆抗体 (mAb),由人 γ 1 重链和人 κ 轻链组成。Toralizumab 可特异性结合 T 细胞上的人 CD40L,从而阻止 CD40 信号传导。Toralizumab 是一种免疫抑制剂。Toralizumab 可导致血栓形成增加。Toralizumab 可用于研究多发性硬化症、系统性红斑狼疮 (SLE) 和克罗恩病等疾病。
    Toralizumab
  • HY-P99445
    Asunercept Inhibitor 98.13%
    Asunercept (APG101; CAN008) 是一种靶向 CD95L 的可溶性 CD95-Fc 融合蛋白。Asunercept 通过选择性地与 CD95L 结合,来破坏 CD95/CD95L 的信号传导。Asunercept 可用于多形性胶质母细胞瘤 (GBM)、骨髓增生异常综合征 (MDS) 以及移植物抗宿主病 (GvHD) 的研究。
    Asunercept
  • HY-113402A
    Gamma-glutamylcysteine TFA

    γ-谷氨酰半胱氨酸(三氟乙酸盐)

    Inhibitor
    Gamma-glutamylcysteine (γ-Glutamylcysteine) TFA 是谷胱甘肽 (GSH) 合成的中间体,一种作为抗氧化酶谷胱甘肽过氧化物酶 (GPx) 的必需辅助因子的二肽。Gamma-glutamylcysteine TFA 上调抗炎细胞因子 IL-10 的水平,降低促炎细胞因子 (TNF-αIL-6IL-1β) 的水平,并减弱在寡聚 Aβ40 处理的星形胶质细胞中金属蛋白酶活性的变化。
    Gamma-glutamylcysteine TFA
  • HY-N6850
    Calenduloside E Inhibitor 99.07%
    Calenduloside E 是一种五环三萜皂苷,可以从楤木的树皮和根中提取得到,具有抗炎和抗凋亡活性。Calenduloside E 通过调节巨噬细胞极化减轻动脉粥样硬化,调节 AMPK-SIRT3 通路改善线粒体功能,减轻急性肝损伤。此外,Calenduloside E 促进 L 型钙通道 (Calcium Channel) 与 Bcl-2 相关凋亡 (apoptosis) 基因相互作用,抑制钙超载,减轻心肌缺血/再灌注损伤。Calenduloside E 还通过调节热休克依赖途径改善非酒精性脂肪肝,抑制 ROS 介导的 JAK1-STAT3 通路减轻细胞炎症反应。
    Calenduloside E
  • HY-N0261
    Aurantio-obtusin

    橙黄决明素

    Inhibitor 99.89%
    Aurantio-obtusin 是一种可以从决明子中提取的蒽醌类化合物。Aurantio-obtusin 具有降血压、降血脂和抗炎的作用。Aurantio-obtusin 是一种口服有效的血管扩张剂。Aurantio-obtusin 通过 AMPK/自噬和 AMPK/TFEB 介导的脂质积累抑制的途径来改善肝脂肪 变性 。
    Aurantio-obtusin
  • HY-19717
    DCVC Inhibitor 99.78%
    DCVC (S-[(1E)-1,2-Dichloroethenyl]-L-cysteine) 是一种三氯乙烯 (TCE) 的生物活性代谢产物。DCVC 可抑制病原体刺激的组织培养物中促炎细胞因子 IL-1β,IL-8TNF-α 的释放。
    DCVC
  • HY-118922
    IW927 Inhibitor 99.23%
    IW927 是一种光化学增强型 TNF-α-TNFR1 相互作用抑制剂,可阻断 TNF-αTNFRc1 的结合,其 IC50 值为 50 nM。IW927 与 TNFRc1 可逆结合,亲和力较弱 (Kd = 40-100 μM),通过光化学反应共价修饰受体,而不与相关的细胞因子受体 TNFRc2 或 CD40 结合。IW927 可破坏 TNFα 诱导的 IκB 磷酸化,其 IC50 值为 600 nM。IW927 可用于开发光非依赖性抑制剂。
    IW927
  • HY-123630
    Allura Red AC

    诱惑红

    Activator 98.01%
    Allura Red AC 是一种食品色素,是一种深红色的水溶性粉末或颗粒,用于各种用途,如饮料、糖浆、糖果和谷物。Allura Red AC 可静态淬灭 HSA 固有荧光。Allura Red AC 还是一种 5-羟色胺 (5-HT) 通路相关的促炎剂,可加剧实验性结肠炎。Allura Red AC 有望用于炎症性肠病 (IBD)、肠道屏障功能及食品添加安全性相关研究。
    Allura Red AC
  • HY-B1197
    Amcinonide

    安西奈德

    Inhibitor 99.61%
    Amcinonide 是 NO 释放的抑制剂 (IC50 = 3.38 nM)。Amcinonide 可抑制神经胶质细胞中 NNC 诱导的促炎基因 iNOSTNF-αIL-1β 的表达。Amcinonide 可减少 T6+/Ia+ 细胞的数量,同时增加 T6+/Ia- 细胞的数量。Amcinonide 可选择性地降低 Ia 抗原的表达。Amcinonide 可用于湿疹性皮炎的研究。
    Amcinonide
  • HY-N1508
    Ecliptasaponin A

    旱莲苷A

    Inhibitor 99.50%
    Ecliptasaponin A 是一种口服有效的五环三萜皂苷。Ecliptasaponin A 通过激活 ASK1/JNK 通路,诱导肺癌细胞凋亡 (apoptosis) 和自噬 (autophagy) 发挥抗肿瘤活性。Ecliptasaponin A 可抑制 HMGB1/TLR4/NF-κB 通路、COX-2MMP9 表达发挥抗炎/抗纤维化作用并保护心血管系统。 Ecliptasaponin A 能增强 SOD 活性、降低 MDA 水平,减轻氧化应激损伤。Ecliptasaponin A 通过抑制 MMP13 的表达、调节炎症因子发挥软骨保护作用。 Ecliptasaponin A 通过上调 ESR1 受体表达,改善卵巢功能,调节性激素。
    Ecliptasaponin A
  • HY-132248
    C5 Lenalidomide Inhibitor 99.62%
    C5 Lenalidomide (Lenalidomide 5'-amine) (Compound 8a) 是沙利度胺类似物,是 TNF-α 的有效抑制剂 (在 LPS 刺激的人 PBMC 中 IC50 = 100 μM,在全血中 IC50 = 480 nM)。
    C5 Lenalidomide
  • HY-161982
    JNU-0921 Agonist 99.77%
    JNU-0921 是一种有效且具有口服有效的 CD137 激动剂。JNU-0921 可增加 IFN-γ 和 GZMB 的 mRNA 表达。JNU-0921 可诱导荧光素酶活性,其 EC50 值为 64.07 nM。JNU-0921 可增强细胞毒性 CD8+ T 细胞 (CTL) 的效应和记忆功能并缓解其衰竭。JNU-0921 还可使辅助 T 细胞向 T 辅助 1 型极化,并增强其活性以增强 CTL 功能。JNU-0921 具有抗癌活性。
    JNU-0921
  • HY-N1482
    Methyl palmitate

    棕榈酸甲酯

    98.0%
    Methyl palmitate 是一种天然存在的脂肪酸酯。Methyl palmitate 能够调节巨噬细胞活性,并下调促炎介质,例如 TNF-α 和一氧化氮 (NO)。Methyl palmitate 具有抗炎和抗纤维化作用。Methyl palmitate 是 ΙκB 磷酸化的强效抑制剂。Methyl palmitate 能够抑制 LPS (HY-D1056) 诱导的库普弗细胞和大鼠腹膜巨噬细胞。Methyl palmitate 能够抑制 RAW 细胞的吞噬功能。Methyl palmitate 对毒蕈碱受体 (muscarinic receptors) 具有拮抗作用。Methyl palmitate 在体内具有对抗缺血/再灌注损伤的心脏保护作用。Methyl palmitate 对朱砂红线虫 (T. cinnabarinus) 成虫具有剧毒。
    Methyl palmitate
  • HY-N2468
    Xylobiose

    木二糖

    98.0%
    Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) 是一种口服有效的 Claudin 2/CLDN2 抑制剂及 HSP27 诱导剂。Xylobiose 通过调节肠道屏障功能及糖脂代谢相关信号通路发挥作用。Xylobiose 抑制 CLDN2 表达以减少肠道通透性,诱导 HSP27 增强细胞保护,同时调控 miR-122a/miR-33a 轴以抑制肝脏脂质合成、改善胰岛素抵抗。Xylobiose 可强化肠道屏障完整性、降低血糖和血脂水平、减轻氧化应激及炎症反应。Xylobiose 可用于 2 型糖尿病及代谢综合征的研究。
    Xylobiose
  • HY-B1051
    Flumethasone

    氟米松

    Inhibitor 99.84%
    Flumethasone (Flumetasone) 是一种具有口服活性,高选择性和有效的糖皮质激素受体 (GR) 激动剂。Flumethasone 激活 GR 抑制核因子 κB (NF-κB) 介导的促炎细胞因子 (TNF-α、IL-1β) 产生,促进抗炎基因 (IL-10) 表达,同时调节代谢酶活性 (酪氨酸转氨酶诱导)。Flumethasone 有望用于炎性疾病、癌症和内分泌调节的研究。
    Flumethasone
  • HY-135674
    SR-318 Inhibitor 98.17%
    SR-318 是一种化学探针,是一种有效且高度选择性的 p38 MAPK抑制剂,对 p38αp38βp38α/β 的 IC50 分别为 5 nM,32 nM 和 6.11 μM。SR-318 有效抑制全血中 TNF-α 的释放,IC50 为 283 nM。SR-318 具有抗癌和抗炎活性。
    SR-318
  • HY-P99812
    Ragifilimab

    拉格芙利单抗

    Agonist
    Ragifilimab (INCAGN-1876) 是一种靶向糖皮质激素诱导的 TNFR 相关蛋白 (GITR) 的激动剂单克隆抗体。Ragifilimab 可用于晚期或转移性实体瘤研究。
    Ragifilimab
  • HY-18377
    Bioymifi Activator 98.0%
    Bioymifi 是一种有效的 TRAIL 受体 DR5 激活剂,与DR5的胞外结构域 (ECD) 结合,Kd 为 1.2 μM,Bioymifi 可作为单一的诱导剂诱导 DR5 的聚集,导致细胞凋亡。
    Bioymifi
  • HY-P990151
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) Inhibitor
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) 是一种抗小鼠 TL1A/TNFSF15 IgG 单克隆抗体。Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) 可以降低 TL1A 水平并阻断 TL1A-DR3 相互作用。Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6) 可用于研究结肠炎和胶原诱导性关节炎 (CIA) 等炎症疾病。
    Anti-Mouse TL1A/TNFSF15 Antibody (5G4.6)
  • HY-139066
    Punicic acid Inhibitor 98.0%
    Punicic acid 是石榴籽油的一种生物活性化合物。Punicic acid 是共轭 α-亚麻酸和 ω-5多不饱和脂肪酸的异构体。Punicic acid 具有抗炎和抗氧化活性,能够抑制炎症介质如肿瘤坏死因子α (TNF-α) 的表达。Punicic acid 还可以通过增加 GLUT4 蛋白的表达和抑制 calpain 的过度激活来减少 β-淀粉样蛋白 (Amyloid-β) 沉积的形成和tau 的过度磷酸化,用于预防和治疗神经退行性疾病。此外,Punicic acid 也具有依赖于脂质过氧化和 PKC 途径的乳腺癌抑制剂特性。
    Punicic acid
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.